

Food supplements marketed worldwide: a comparative analysis between the European and the U.S. regulatory frameworks

Authors: Andrea Zovi^{1,4}, Antonio Vitiello², Michela Sabbatucci², Umberto Maria Musazzi³, Gianni Sagratini⁴, Carlo Cifani⁴, Sauro Vittori⁴

Affiliations:

1. Directorate General for Hygiene, Food Safety and Nutrition, Ministry of Health, viale G. Ribotta 5, 00144, Rome, Italy
2. Directorate General for Health Prevention, Ministry of Health, viale G. Ribotta 5, 00144, Rome, Italy
3. Department of Pharmaceutical Sciences, University of Milan, via G. Colombo, 71, 20133, Milan Italy
4. School of Pharmacy, University of Camerino, Via Sant'Agostino 1, 62032 Camerino, Italy

Corresponding author: Andrea Zovi. Postal address: andrea.zovi@unicam.it; Phone number: +393473727794.

Abstract: In recent decades, a new health paradigm emerged which increasingly places diet and nutrition at the center of citizens' healthcare. The resulting evolution of the food market has prompted country governments to adapt their regulatory frameworks to ensure product safety and preserve the health of citizens. Dietary supplements (DS) are products which are increasingly occupying a significant market share in Western countries, contributing to meeting the nutritional and physiological needs of a large portion of the global population. Food supplements must be safe for use by the final consumer who has access to the global market, but currently they are framed by a different legislation worldwide. This search aimed of comparing the legislative frameworks currently in force in the European Union (EU) and in the United States (USA), the two main markets in which DS are purchased, to focus on the strengths, similarities and possible shortcomings, against the backdrop of a global market which often transcends the regulatory barriers of individual countries. Both in the EU and the USA, food supplements are governed by specific regulations to ensure their safety and quality. However, the regulatory approaches differ sharply in some cases. It is expected that more and more operators will launch new DS in Western markets. As a result, it is crucial for competent authorities in food safety to deepen and develop additional regulatory tools aimed to control and safeguard the DS market.

Highlights

- The resulting evolution of the food market has prompted country governments to adapt their regulatory frameworks to ensure food safety and safeguard the health of citizens
- Food supplements must be safe for use by the final consumer who has access to the global market, but currently they are framed by a different legislation worldwide
- Both in the EU and the USA, the two main markets in which DS are purchased, food supplements are governed by specific regulations to ensure their safety
- Nevertheless, the regulatory approaches differ sharply in some cases
- As a result, it is crucial for competent authorities to develop additional regulatory tools aimed to control and safeguard the DS market

Key words: dietary management, food supplements, regulatory framework, comparative legislation

Introduction

Having an equilibrate diet has become central in preserving citizens' health in most of western countries [1]. Consequently, the food industry evolved from suppliers of essential goods for human nutrition to providers of food-derived products, enriched with novel substances with health effects able to provide a nutritional supplementation of people body's functions. In parallel, the globalization has enlarged the international foods' movements, permitting to exotic foods to reach markets and consumers never reached before. Such an evolution of the food market has pushed authorities to adapt their regulatory framework to ensure the safety

57 of products and to preserve citizens' safety. On one side, the increased availability of exotic foods forced the
58 regulatory authorities to lighting up borderline situations, avoiding the marketing of products containing
59 molecules with a pharmacological action. On the other side, the increased interest of the healthcare community
60 for nutritional aspects in the treatment and prevention of human diseases and the regulatory qualification of
61 foods have increased its complexity over the years in order to distinguish among foods, foods for specific
62 groups of populations, foods enriched of substance not naturally present in them, products intended to integrate
63 the standard diet like food supplements (FS)/dietary supplements (DS) [2,3]. They must be safe for use by the
64 final consumer, and currently they are framed by a different legislation in the United States of America (USA),
65 in the European Union (EU), in the Asia Pacific countries or in other realities worldwide [4]. Among foods,
66 DS belong to the category of products most marketed worldwide and most purchased by consumers [5-7].
67 However, people often refer to DS without having clear the regulatory framework to which they belong
68 regarding food safety field [8]. In addition, to date there is no globally harmonized definition regarding the
69 category of products known as nutraceuticals, natural products, products that often, from a regulatory
70 perspective, are actually DS [9]. Furthermore, it is noteworthy that a product which is considered a food
71 supplement and regulated as food under a specific regulation may be considered a medicinal product if placed
72 under another legislative framework [7-10]. From the above, the present review is aimed at comparing the
73 present legislation between USA and EU, the main DS markets, to focus on the strengths, similarities and
74 possible shortcomings, against the backdrop of a global market, which often transcends the regulatory barriers
75 of individual countries.

76 77 *Food supplements global market*

78
79 The global DS market is a rapidly growing industry, with a market size of approximately \$140 billion in 2020
80 [5]. The market is driven by an increasing focus on preventive healthcare by aging populations and growing
81 interest by people in fitness and wellness. In fact, the global DS market has been on the rise in recent years
82 due to increasing health concerns and rising awareness among consumers about the benefits of supplements
83 [1,5,6,8]. Vitamins and minerals are the largest product categories, accounting for around 35% of sales,
84 followed by botanicals and herbal supplements. North America is the largest regional market, followed by
85 Europe and the Asia Pacific [11,12]. In parallel, online sales are increasing in popularity, due to several factors,
86 such as the convenience and the COVID-19 outbreak [5,13-15]. In the USA, the DS market has been steadily
87 growing, with a current estimated value of over \$30 billion. Vitamins and minerals are the most commonly
88 consumed DS also in the USA. However, other categories, such as herbal supplements and sports nutrition
89 products, have also seen significant growth in recent years. Online sales of DS have also been on the rise in
90 the USA, with consumers preferring the convenience of online shopping and the availability of a wider range
91 of products. In the EU, the FS market has also been growing, with a current estimated value of over €12 billion
92 [11]. The demand for FS in the EU is driven by similar factors as in the USA, such as increasing health concerns
93 and interest in preventive healthcare: vitamins and minerals are also the most commonly consumed FS in the
94 EU. Overall, a number of factors caused an increase in the FS/DS consumption in Western populations in
95 recent years, but in particular the COVID-19 outbreak has largely stimulated the sale and purchase of FS/DS
96 in the USA and the EU, regions where the dietary supplement industry is largely concentrated [13]. Therefore,
97 the market is expected to see a further increase in the demand for immunity-boosting supplements, and the
98 global dietary supplements market size is expected to expand at a compound annual growth rate of about 8.9
99 % until 2030 [11].

100 101 102 **Legislative frameworks**

103 *Class of food derivatives*

104
105
106 As well as for other foods, such as foods for special medical purposes or gluten-free foods, the regulatory
107 framework applicable to FS in Europe is particularly stratified. As other foods, the regulatory framework on
108 FS is constituted both by acts applicable to all foods and those more specific for such regulatory class. In
109 particular, since FS are essentially foods for the EU legislation, the Regulation (EC) no. 178/2002 is applicable
110 to them. Such Regulation establishes the principles and general requirements of the food law laying down
111 European competences and procedures in the field of food safety, with the aim at guaranteeing a high level of
112 protection either for human health or for the interest of consumers in relation to food [16]. In light of the

113 regulation, food is defined as “any substance or product, whether processed, partially processed or
114 unprocessed, intended to be, or reasonably expected to be ingested by humans”. The term “food” includes
115 beverages, chewing gum and any substance, including water, intentionally incorporated into food during its
116 manufacture, preparation or processing. The term “food” does not include feed, live animals unless they are
117 prepared for placing on the market for human consumption, plants before harvesting, medicines under Council
118 Directives 65/65/EEC and 92/73/EEC, tobacco and tobacco products under Council Directive 89/622/EEC,
119 cosmetics products, residues, and contaminants. The FS are regulated also by Directive 2002/46/EC, which
120 defined them as foods intended to supplement the normal diet and which constitute a concentrated source of
121 nutrients or other substances having a nutritional or physiological function (art. 2). FS can be developed both
122 mono- and multi-compounds, in pre-measured forms, e.g., capsules, tablets, liquids contained in vials, dropper
123 bottles and other similar forms of liquids and powders intended to be taken in small unit quantities [17].
124 In the USA, dietary supplements are regulated by most of same provisions of law that are applied to foods, the
125 Federal Food, Drug and Cosmetic Act 4. However, following amendments passed by Congress in 1994, known
126 as the Dietary Supplement Health and Education Act (DSHEA), DS are also subjected to specific provisions
127 that do not apply to conventional food [18,19]. DSHEA defined DS any products intended to supplement the
128 diet. Moreover, DSHEA determined that DS can take the form of conventional food-like cereal, candy bars -
129 but cannot represent themselves as a conventional food. The definition of DS is contained in the section 201
130 of the Federal food, drug, and cosmetic act (FD & C Act) [19]. In particular, the definition quotes that “a
131 dietary supplement...is a dietary substance for use by man to supplement the diet by increasing the total
132 dietary intake”. This definition restricts the scope of substances to be included in DS and called “dietary
133 ingredients”, potentially including all food additive substances but excluding substances previously approved
134 as active ingredients with pharmacological activity [19-20].

135
136

137 *Content of ingredients and substances characterizing the composition of food and dietary supplements*

138

139 The ingredients characterizing the composition of FS may be vitamins, minerals, plants or other substances
140 like amino acids, fibers, probiotics, prebiotics. Overall, in the EU ‘other substances’ are defined in article 2 of
141 Regulation (EC) 1925/2006 as “substances other than vitamins and minerals with a nutritional or physiological
142 effect”, whereas vitamins and minerals and their forms that may be added to foods, including FS, are listed in
143 Regulation (EC) 1170/2009, amending Directive 2002/46/EC [21-22]. According to the regulation, the
144 minimum level of vitamins and minerals present in FS must be significant, thus at least 15% of the nutritional
145 reference value (NRV); maximum levels are not currently harmonized in the EU. However, the expected daily
146 intake limits for vitamins, minerals and the other ingredients contained in FS may be regulated at the level of
147 individual countries, based on scientific risk assessments. For instance, in Italy, reference is made to some lists
148 drawn up by Competent Authority (CA) which includes the threshold of the daily intake foreseen for vitamins
149 and minerals in FS, and other substances other than vitamins and minerals having a nutritional or physiological
150 effect, allowed to be used in FS [23]. Similarly, a list of plants and related plant parts that can be used in foods
151 and thus in FS has been released in Belgium, France and Italy, depending on particular properties, which the
152 plants have to maintain specific nutritional or physiological activities. Where established, limits of allowable
153 intake with daily dose and additional warnings are also given, based on risk assessments carried out. This was
154 an international initiative which involves several EU member states and was drawn up by Belgium, France
155 and Italy as the first step in an agreed project to achieve a common framework on the use of plants and
156 derivatives in the field of food supplements, with the aim of also promoting harmonization of the subject at
157 the European level [24]. Further specific provisions for the regulation of ‘other substances’ are outlined in
158 article 8 of Regulation (EC) 1925/2006 which provides a procedure to address the safety concerns associated
159 with any sub-stances other than vitamins and minerals used in food, including FS [21]. In particular, the EU
160 Commission may initiate the ‘Article 8 procedure’ in order to include a certain substance on a list to prohibit
161 (Annex III Part A), restrict (Annex III Part B) or to put it under community scrutiny to be reviewed within 4
162 years (Annex III Part C). Among the ingredients in the FS, all the food products or substances, vegetables
163 preparations or extracts without significant consumption history before May 15, 1997 qualify as novel foods
164 under Regulation (EU) 2015/2283 [25]. All the novel foods need to be authorized by the European Commission
165 (EC), after the assessment of safety carried out by the European Food Safety Authority (EFSA). Furthermore,
166 the Commission Implementing Regulation (EU) 2017/2470 (Union List of authorized novel foods) establishes
167 a list of all the authorized novel foods in the EU, including their conditions of use, labelling requirements and
168 their specifications, and it is amended following each new authorization.

169 In the USA, unlike other categories of products, which are classified according to their intended use, such as
170 medicines or cosmetics, in order to be regulated as a DS a product must contain at least one of the following
171 dietary ingredient listed in the FD & C Act: vitamin, mineral, botanical, amino acids, acids or other dietetic
172 substances used by humans to supplement the diet by increasing total dietary intake or concentrates,
173 metabolites, constituents, extracts or combinations of these ingredients. Therefore, if a product does not contain
174 any of the above ingredients, it does not meet the definition of a DS [19,26]. Current U.S. regulations do not
175 prohibit the marketing of dietary supplements containing pharmacologically active molecules. However, any
176 substance approved as a new drug is excluded from the definition of a dietary supplement, unless the item was
177 marketed as a dietary supplement or food prior to its approval as a new drug [27-28]. Moreover, the Food
178 Business Operator (FBO) must notify the Food and Drug Administration (FDA) before marketing products
179 with new dietary ingredients (NDI). Manufacturers of NDI must notify FDA 75 days prior to the introduction
180 of a DS containing the ingredient into the market. NDI are defined as ingredients that have been not marketed
181 in the USA prior to October 15, 1994 [19,26]. Any required notification must include information on which
182 FBO have based their conclusion of a reasonable expectation of safety. Furthermore, based on the DSHEA
183 safety standards, the FDA maintains the authority to recall certain ingredients from the market, for example in
184 the case of products containing the Chinese herb ma huang (*Ephedra sinensis*) in 2004, based on the
185 determination of “risk unreasonable” for health [29].
186

187 *Place on the market*

188

189 Both in the EU and the USA, FS and DS do not require a formal authorization by a competent authority, as for
190 medicinal products, for being placed on the market.

191 In the EU, FS are subject to a notification procedure, where the manufacturer notifies the competent national
192 authority of their intention to market the product. Only in the case of FS containing novel or innovative
193 ingredients, falling under the Novel Foods Regulation or if its label contains a health claim falling under the
194 Regulation 1924/2006, pre-market authorization should be obtained.

195 DS in the United States are regulated by the FDA, but do not require FDA pre-market approval or a pre-market
196 notification process.
197

198 *Manufacturing*

199

200 The FS production in the EU and USA markets involves a series of regulatory processes to ensure their safety
201 and quality. In Europe, under Regulation (EC) n. 178/2002 and Directive 2002/46/EC, the production and
202 packaging of FS follow the provisions generally established for foods. As an example, they are subject to the
203 approval of the manufacturing and/or packaging establishment with the competent national health authority:
204 e.g., in Italy such aspects are regulated at local level. The FBO that notifies and places the product on the
205 market is obliged to include on the label the mandatory indication of the FBO responsible for ensuring
206 product’s compliance with the regulations, complete with name and address. In cases where production is
207 outsourced to a third party, priority should be given to information on the responsible FBO. Any secondary
208 information may follow that relating to the responsible FBO. As stipulated in the regulations, all operators
209 who are involved in the food production chain of post-primary sectors must apply self-control to production
210 in a rational and organized manner, according to the principles of HACCP (Hazard analysis and critical control
211 points). The HACCP system is a tool intended to help FBOs achieve a higher level of food safety. The plan
212 should aim to prevent the causes of nonconformities before they occur and should provide for appropriate
213 corrective actions to minimize risks when, despite the implementation of preventive measures, nonconformity
214 occurs. The main objective is to establish a documented system by which the FBO can demonstrate that it has
215 operated in a way that minimizes risk under its own responsibility.

216 In the USA, DS manufacturing facilities are subject to the same registration requirements applicable to food
217 manufacturing facilities per the Public Health Security and Bioterrorism Preparedness and Response Act of
218 2002 additions to section 410 of the Federal Food, Drug, and Cosmetic act. Moreover, regulatory requirements
219 for ingredient quality in DS are codified in 21 CFR Part 111 (Current Good Manufacturing Practice in
220 Manufacturing, Packaging, Labelling, or Holding Operations for Dietary Supplements) [30]. These regulations
221 define “quality” to mean that the DS consistently meets the specifications established for identity, purity,
222 strength, and composition, and adheres to limits on contaminants [31]. Manufacturers are required to follow
223 Good Manufacturing Practice (GMP) guidelines for the production, packaging, labeling, and storage of DS.
224 Compliance with FDA GMP regulations is essential to ensure product safety and quality. The GMP

225 regulations, aimed at achieving comprehensive quality systems, require manufacturers to verify that laboratory
226 examination and testing methods are appropriate for their intended use and to scientifically identify and use
227 validated and appropriate methods for each established specification [32].

228 229 *Labelling and claims*

230
231 By understanding the regulatory framework behind claims and label statements, consumers can make more
232 informed decisions and health care professionals can better assist their patients.

233 Overall, in the EU European Regulation 1169/2011 broadly defines the principles, requirements and
234 responsibilities governing mandatory food information and, in particular, food labeling. Furthermore, as
235 required by article 6 of Directive 2002/46/EC, FS labeling bears the following mandatory elements: the name
236 of the nutrients that characterize the product, the recommended daily intake, a warning not to exceed the
237 recommended dosage, a statement that supplements are not intended as a substitute for a varied diet, eventually
238 that they should be kept out of the reach of children under three years of age. Furthermore, the same article
239 requires that the food information cannot attribute to these products the property of preventing, treating or
240 curing a human disease or relate to such properties. Claims allowed to the FS labels are classified in health
241 and nutritional claims. Overall, Regulation 1924/2006 establishes the rules for the use of nutritional and health
242 claims, which can be claimed voluntarily by FBO on foods labels, and thus in particular on FS [33]. The
243 purpose of the regulation is to harmonize the legislation of the Member States, to promote innovation, to favor
244 the free circulation of foods and fair competition between operators as well as to guarantee clear, truthful and
245 science-based information, with the aim at guiding and protecting the consumer, encouraging conscious
246 choices. When referenced to nutritional indications, it means any indication which states, suggests or implies
247 that a food owns particular beneficial nutritional properties, due to the energy it provides and the nutrients it
248 contains or does not contain. On the other hand, when referenced to health claims, it means any claim which
249 states, suggests or implies the existence of a relationship between a specific food component and health. Health
250 claims are classified in health claims other than those on the reduction of risk of disease, health claims relating
251 to decreasing the risk of disease and health claims relating to the health and development of children. Both
252 health and nutritional claims which can be used in the FS labeling must be authorized in advance by EC
253 supported by EFSA, that, on the basis of the scientific evidence, which may support the use of a particular
254 claim, provides a positive or negative opinion on its use. For the purpose of proper communication to the
255 consumer, without prior authorization, no claim can be used by the FBO. The list of claims authorized by the
256 EC with their regulatory references is public and available for consultation by all European citizens [34].

257 In the USA, the FBO is responsible for the safety and labeling of the marketed product. As required by the
258 Act, manufacturers cannot make specific claims about disease treatment, only with reference to nutritional
259 support and any information related to physiological functions. Regulations cover three types of claims for
260 food and dietary supplements: health, nutrient content and structure/function claims [18,35-37].

261 *Health claims* describe the relationship between a food substance and reduced risk of a disease or health-
262 related condition. The FDA oversees health claims on food and dietary supplement labels through three main
263 avenues: the 1990 Nutrition Labeling and Education Act (NLEA), the 1997 Food and Drug Administration
264 Modernization Act (FDAMA), and the FDA's Interim Procedures for Qualified Health Claims.

- 265 • NLEA Authorized Health Claims are based on scientific evidence reviewed by the FDA. They must
266 meet a significant scientific agreement standard, for instance how the intake of a mineral may
267 reduce the risk of a specific illness
- 268 • Health Claims Based on Authoritative Statements (FDAMA) can be authorized based on authoritative
269 statements from recognized scientific bodies or government agencies. These claims are not applicable
270 to dietary supplements. Firms must submit notifications to the FDA, and these claims can be used after
271 120 days unless the FDA objects.
- 272 • When scientific evidence is emerging but not conclusive, the FDA reviews petitions for qualified
273 health claims. If the evidence is credible, the FDA issues letters of enforcement discretion with
274 qualifying language to prevent misleading consumers. These claims indicate that supporting evidence
275 is limited.

276 A health claim must include two components: a substance (food, food component, or dietary ingredient) and
277 a disease or health-related condition. Statements lacking these components are considered dietary guidance or
278 structure/function claims and do not require premarket review by the FDA.

279 *Structure/Function Claims* describe the role of a nutrient or dietary ingredient in maintaining normal body
280 structures or functions. Unlike health claims, these do not link the nutrient to disease prevention and do not
281 require FDA pre-approval. Manufacturers must substantiate these claims and notify the FDA within 30 days
282 of marketing. Structure/function claims for conventional foods focus on nutritive value effects, while those
283 for dietary supplements may include non-nutritive effects. Dietary supplements with structure/function claims
284 must include a disclaimer that the FDA has not evaluated the claim and that the product is not intended to
285 diagnose, treat, cure, or prevent any disease.

286 *Nutrient Content Claims* are authorized by the NLEA, and describe the level of a nutrient in a product using
287 terms like “free,” “high,” “low,” or comparative terms like “more,” “reduced,” “lite.” Such claims must comply
288 with FDA regulations to ensure consistency and meaning for consumers, for instance how a specific
289 quantity of a mineral may imply a low level and must meet criteria for such a claim.

290
291 *Distribution and consumers’ access to products*

292
293 In the EU, FS are widely available and can be purchased from various outlets, including pharmacies,
294 supermarkets, and online platforms. The purchase of FS can be made without the need to have a doctor’s
295 prescription. On the other hand, there are several diseases such rare diseases but also more common diseases,
296 as hypertension, that need a specific dietary management of the illness [38,39]. Thus, in some cases people
297 suffering from pathologies or medical conditions that determine a nutritional vulnerability need the taking of
298 FS, in conjunction with administration of medicine. Therefore, in these cases in some European countries, FS
299 can leverage the reimbursement through the national health services, which ensure the continuity of care to
300 patients who need an integrative care.

301 In the USA, DS are widely available and can be bought at different points of sale, including pharmacies,
302 supermarkets and online platforms. DS may be purchased without the need for a physician’s prescription. DS
303 cannot be reimbursed through American Flexible Spending Accounts. However, in patients with a specific
304 medical condition diagnosed by a physician, DS recommended by a doctor as treatment for this condition are
305 tax-deductible medical expenses [40].

306
307 *Post-market surveillance*

308 In the EU, as well as for other food products, the placing on the market of FS falls under the direct responsibility
309 of the FBO, who is responsible for its safety. FBO is required to monitor the safety of products manufactured
310 and placed on the market based on the evolution of scientific knowledge. In this regard, FBO is required to
311 communicate to the competent authority any new data it knows about side or unexpected effects of the
312 ingredients used in its products. However, the competent national authorities of the Member States can always
313 carry out inspections and request information as part of the official control. Furthermore, at European level the
314 Rapid Alert System for Food and Feed was established by Reg 178 2002 in the form of a network, to which
315 the EC, EFSA and the EU Member States belong. The RASFF represents an effective tool that provides control
316 authorities with a fast, efficient and European-wide mechanism, to exchange information on the measures
317 adopted to guarantee food safety.

318 In the US the law includes a post-market inspection process for manufacturing sites to assess compliance with
319 GMP and the reporting of potential serious adverse effects by FBO. In particular, FBO must submit all reports
320 of significant adverse events linked to the usage of the DS to the FDA, no later than 15 business days after the
321 report is received by the responsible person [29].

322
323
324 **Discussion - Expert opinion**

325
326 Both in the USA and the EU, FS and DS are governed by specific regulations to ensure their safety and quality.
327 Both legislations do not require a market authorization for these food products but assign the responsibility to
328 the FBO, to guarantee the safety of the FS/DS and ensure transparency in providing accurate information to
329 citizens after the product is placed on the market. In particular, European FS and American DS facilities and
330 products are subject respectively to state and federal post-market control and inspection. The definition of a
331 FS/DS is overlapping since it is primarily considered a food product, regulated by a more general regulation
332 applicable to all ordinary foods. Secondly, it is classified as a specific food intended to supplement the common
333 diet, providing a concentrated source of nutrients. However, the regulatory approaches differ in some cases.
334 In the USA, the legislation primarily focuses on compliance with labeling and production practices, as well as

335 post-marketing surveillance under the FD&C Act - section n. 201 regulation. On the other hand, in the EU,
336 several regulations specifically govern FS. First, in the EU, the FBO is obliged to notify the FS to the competent
337 authority of each individual member state where it sells the product. The competent authority may
338 subsequently conduct checks on the products and their composition, also in collaboration with local health
339 authorities. Moreover, unlike the FDA, which assesses only specific health claims before release the approval,
340 the EU has issued a regulation on both nutritional and health claims; beyond that a specific regulation on novel
341 ingredients defined as “novel foods”, if they do not have a significant history of consumption in the EU before
342 1997. Both these regulations require authorization, based on scientific evidence available in the literature and
343 in favor of food safety. In fact, in the EU, EFSA plays a unique role in providing scientific opinions at the
344 community level to protect consumers in the consumption of FS, supporting the EC. Furthermore, significant
345 progress has been made in the EU in listing permitted and employable substances in food through official lists,
346 such as vitamins, minerals, and other substances. In some cases, these lists are based on specific risk
347 assessments for certain ingredients conducted by individual member states. In the USA, there is no specific
348 legislation governing the market entry of novel food ingredients and there is no list of permitted nutrients with
349 corresponding daily dose limits. In fact, the NDI notification process is subject of a significant series of historic
350 litigation without consistent enforcement, with the FDA conservatively estimating that as many as 3,500 NDI
351 have not filed notifications under current law [41]. Draft regulations are currently pending to establish a
352 temporary period of enforcement discretion to address the lack of enforcement of the NDI notifications.
353 Overall, the European legislative framework seems to have more specific regulations in favor of consumer
354 safety than the American one. In particular, the absence of US market entry notification to regulators is perhaps
355 the strongest point of contrast between the two systems. On the other hand, similar to European regulations,
356 US ones also provide for serious safety assessment in relation to health claims that can be affixed to dietary
357 supplement labels. The difference in market values between the two regions is well known, providing a
358 comprehension of some less regulatory restrictions imposed on American food operators. However, it is
359 noteworthy that consumer access to FS/DS is relatively unlimited in both markets, with a wide range of
360 products available for purchase not only in traditional channels such as pharmacies, but also in supermarkets
361 and online stores. Considering that FS/DS are not prescribed by general practitioners or physicians, and
362 consumers have unrestricted access, it is crucial for both American and European citizens to be aware of the
363 regulations, consciously read labels, and make informed choices when purchasing and using FS/DS. It is
364 crucial for competent authorities in both regions to continue regular monitoring the application of existing
365 food safety regulations by the FBO and to promote health care professionals’ qualifications and training in the
366 field to better assist their patients, to guarantee product quality in the market and protect consumer safety,
367 respectively.

368 **Conclusions**

371 Food supplements are products increasingly occupying a significant market share in Western countries,
372 contributing to meeting the nutritional and physiological needs of a large portion of the global population. The
373 consumer’s freedom of access to this market, as well as the wide variability of ingredients and substances
374 contained in these products, necessarily focus on regulations that protect consumer safety in the DS use. The
375 American and European markets are regulated by general and specific regulations, particularly in Europe,
376 where several specific regulations govern this particular category of food, making it the region which currently
377 has the most stringent regulations for this market worldwide. However, the responsibility still lies with the
378 food business operator, who must ensure the safety of the marketed product and comply with applicable
379 regulations. It is expected that more and more operators will launch new food supplements in Western markets.
380 As a result, it is crucial for competent authorities in food safety to deepen and develop additional regulatory
381 tools aimed to control the food supplement market, emphasizing the scientific evidence supporting the
382 nutritional and health aspects, which ensure consumer safety when using these products, in protection of an
383 increasing global market.

384 **Contributions:**

386 Andrea Zovi (A.Z.), Michela Sabbatucci (M.S.), Antonio Vitiello (A.V.), Umberto Maria Musazzi (U.M.M.), Gianni
387 Sagratini (G.S.), Carlo Cifani (C.F.), Sauro Vittori (S.V.).
388 Conceptualization, A.Z., U.M.M., A.V., S.V; methodology, A.Z., U.M.M; investigation, A.Z., A.V., M.S.; writing -
389 original draft preparation, A.Z., U.M.M, A.V.; writing - review and editing, M.S., G.S., C.C., S.V.; visualization, U.M.M.,
390 G.S., C.C., S.V..

391 All the authors have read and agreed to the published version of the manuscript.
392
393

394 **Acknowledgments:** none.
395

396 **Grant support or other sources of funding:** this research received no external funding.
397

398 **Conflict of interests:** The authors declare that they have no known competing financial interests or personal relationships
399 that could have appeared to influence the work reported in this paper.
400

401 **Disclosure:** the authors declare they have used neither AI nor AI-assisted technologies in this work.
402

403 **Disclaimer:** A.Z., A.V. and M.S. declare that the opinions expressed are of a personal nature and do not in any way
404 commit the responsibility of the Administrations to which they belong.
405

406 **Ethical approval:** not applicable.
407

408 **Consent to participate:** not applicable.
409

410 **Consent to publish:** the authors consent to the publication of the manuscript.
411

412 **Availability of data and materials:** full availability of data and materials.
413

414 **Copyright:** the authors certify that the manuscript is original, never submitted to other journal for publication before. All
415 authors contributed equally to the manuscript and had the opportunity to revise and approve the final text.
416

417

418 **References**

- 419 1. Aleta A, Brighenti F, Joliet O et al. A Need for a Paradigm Shift in Healthy Nutrition Research. *Front Nutr.*
420 2022; 9: 881465. Published online 2022 Apr 19. doi: 10.3389/fnut.2022.881465
421 2. Coppens P, Fernandes da Silva M, Pettman S. European regulations on nutraceuticals, dietary supplements and
422 functional foods: A framework based on safety. *Toxicology* 2006 Apr 3;221(1):59-74.
423 doi:10.1016/j.tox.2005.12.022.
424 3. Zovi A., Langella R., Nisic A., Vitiello A., Musazzi U.M. Liver injury and dietary supplements: Does
425 hydroxycitric acid trigger hepatotoxicity? *Journal of integrative medicine* 2022. doi: 10.1016/j.joim.2022.05.003
426 4. Y Ng J, Kim M, Suri A. Exploration of facilitators and barriers to the regulatory frameworks of dietary and
427 herbal supplements: a scoping review. *J Pharm Policy Pract.* 2022 Sep 5;15(1):55. doi: 10.1186/s40545-022-
428 00447-7.
429 5. Lordan R. Dietary supplements and nutraceuticals market growth during the coronavirus pandemic -
430 Implications for consumers and regulatory oversight. *PharmaNutrition.* 2021 Dec;18:100282. doi:
431 10.1016/j.phanu.2021.100282.
432 6. Arun S, Bhatnagar S, Menon S, Saini S, Hari P, Bagga A. Efficacy of zinc supplements in reducing relapses in
433 steroid-sensitive nephrotic syndrome. *Pediatr Nephrol.* 2009 Aug;24(8):1583-6. doi: 10.1007/s00467-009-1170-
434 5
435 7. Santini A, Cammarata SM, Capone G, Ianaro A, Tenore GC, Pani L, Novellino E. Nutraceuticals: opening the
436 debate for a regulatory framework. *Br J Clin Pharmacol.* 2018 Apr;84(4):659-672. doi: 10.1111/bcp.13496
437 8. Molin TRD, Camera Leal G, Sabo Müller L et al. Regulatory framework for dietary supplements and the public
438 health challenge. *Rev Saude Publica.* 019 Oct 21;53:90. doi: 10.11606/s1518-8787.2019053001263.
439 9. Chopra AS, Lordan R, Horbańczuk OK, Atanasov AG, Chopra I, Horbańczuk JO et al. The current use and
440 evolving landscape of nutraceuticals. *Pharmacol Res.* 2022 Jan;175:106001. doi: 10.1016/j.phrs.2021.106001.
441 10. Thakkar S, Anklam E, Xu A, Ulberth F, Li J, Li B et al. Regulatory landscape of dietary supplements and herbal
442 medicines from a global perspective. *Regul Toxicol Pharmacol.* 2020 Jul;114:104647. doi:
443 10.1016/j.yrtph.2020.104647.
444 11. Grand View Research. Dietary Supplements Market Size, Share & Trends Analysis Report By Ingredient
445 (Vitamins, Minerals), By Form, By Application, By End User, By Distribution Channel, By Region, And
446 Segment Forecasts, 2022 - 2030. Available online: [https://www.grandviewresearch.com/industry-](https://www.grandviewresearch.com/industry-analysis/dietary-supplements-market)
447 [analysis/dietary-supplements-market](https://www.grandviewresearch.com/industry-analysis/dietary-supplements-market). [Accessed on 2023 Mar 6]
448 12. GLGInsights. The Nutraceuticals Market Is Booming. Will It Last? Available online:
449 <https://glginsights.com/articles/nutraceutical-industry-update/>. [Accessed on 2023 Feb 20]

- 450 13. Grebow J. Dietary Supplement Sales Success post-COVID: How Can Industry Keep the Momentum Going After
451 the Pandemic? Available online: [https://www.nutritionaloutlook.com/view/dietary-supplement-sales-success-](https://www.nutritionaloutlook.com/view/dietary-supplement-sales-success-post-covid-how-can-industry-keep-the-momentum-going-after-the-pandemic)
452 [post-covid-how-can-industry-keep-the-momentum-going-after-the-pandemic](https://www.nutritionaloutlook.com/view/dietary-supplement-sales-success-post-covid-how-can-industry-keep-the-momentum-going-after-the-pandemic). [Accessed on 6 March 2023].
- 453 14. Vitiello A, La Porta R, Trama U, Ferrara F, Zovi A, Auti AM et al. Pandemic COVID-19, an update of current
454 status and new therapeutic strategies. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 2022, 395(10), pp.
455 1159–1165.
- 456 15. Ferrara F, Mancaniello C, Varriale A et al. COVID-19 mRNA Vaccines: A Retrospective Observational
457 Pharmacovigilance Study. *Clin Drug Investig*. 2022 Dec;42(12):1065-1074. doi: 10.1007/s40261-022-01216-9
- 458 16. Regulation (EC) No. 178/2002 of the European Parliament and of the Council of 28 January 2002. Official
459 Journal L 031, 01/02/2002, pp. 0001–0024.
- 460 17. Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002.
- 461 18. Taylor CL. Regulatory Frameworks for Functional Foods and Dietary Supplements. *Nutr Rev*. 2004
462 Feb;62(2):55-9. doi: 10.1111/j.1753-4887.2004.tb00024.x.
- 463 19. Federal food, drug, and cosmetic act (FD&C Act), section n.201.
- 464 20. Dietary Supplement Health and Education Act (DSHEA), 1994
- 465 21. Regulation (EC) 1925/2006 of December 20, 2006
- 466 22. Regulation (EC) 1170/2009 of November 30, 2009
- 467 23. Italian Ministry of Health. Available online:
468 https://www.salute.gov.it/portale/temi/p2_5.jsp?lingua=italiano&area=Alimenti%20particolari%20e%20integratori&menu=integratori. [Accessed on 2023 Mar 7]
- 469 24. Cousyn G, Dalfrà S, Scarpa B, Geelen J, Anton R, Serafini M et al. Project belfrit: Harmonizing the use of plants
470 in food supplements in the european union: Belgium, france and italy - a first step. *European Food and Feed*
471 *Law Review*, 2013, 8(3), pp. 187–196
- 472 25. Regulation (Eu) 2015/2283 of the European Parliament and of the Council of 25 November 2015.
- 473 26. Dwyer JT, Coates PM, Smith MJ. Dietary Supplements: Regulatory Challenges and Research Resources.
474 *Nutrients*. 2018 Jan 4;10(1):41. doi: 10.3390/nu10010041.
- 475 27. FDA. WARNING LETTER. Dr. Sam Robbins, Inc. dba HFL Solutions, LLC MARCS-CMS 608729 - AUGUST
476 28, 2020 Available from: [https://www.fda.gov/inspections-compliance-enforcement-and-criminal-](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dr-sam-robbins-inc-dba-hfl-solutions-llc-608729-08282020)
477 [investigations/warning-letters/dr-sam-robbins-inc-dba-hfl-solutions-llc-608729-08282020](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dr-sam-robbins-inc-dba-hfl-solutions-llc-608729-08282020). [updated 2020 Oct
478 6]
- 479 28. Noonan C, Patrick Noonan W. Marketing dietary supplements in the United States: a review of the requirements
480 for new dietary ingredients. *Toxicology*. 2006 Apr 3;221(1):4-8. doi: 10.1016/j.tox.2006.01.010.
- 481 29. Sarma N, Upton R, Rose U, Guo DA, Marles R, Khan I, Giancaspro G. Pharmacopeial Standards for the Quality
482 Control of Botanical Dietary Supplements in the United States. *J Diet Suppl*. 2023;20(3):485-504. doi:
483 10.1080/19390211.2021.1990171.
- 484 30. FDA. Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for
485 dietary supplements; Final rule. Title 21 Code of Federal Regulations Part 111, §§ 111.1-111.610 (Revised April
486 1, 2011); 2007. Available from: <http://edocket.access.gpo.gov/2007/07-3039.ht> [accessed 2021 Sep 10]
- 487 31. ICH. ICH Topic Q 6 A. Specifications: Test procedures and acceptance criteria for new drug substances and
488 new drug products: Chemical substances; 2000 [updated 2021 Sep 10]. Available from:
489 [https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-6-test-procedures-acceptance-criteria-](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-6-test-procedures-acceptance-criteria-new-drug-substances-new-drug-products-chemical_en.pdf)
490 [new-drug-substances-new-drug-products-chemical_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-6-test-procedures-acceptance-criteria-new-drug-substances-new-drug-products-chemical_en.pdf).
- 491 32. Sarma N, Giancaspro G, Venema J. Dietary supplements quality analysis tools from the United States
492 Pharmacopeia. *Drug Test Anal*. 2016;8(3–4):418–23. doi:10.1002/dta.1940.
- 493 33. Regulation (EC) No. 1924/2006 of the European Parliament and of the Council of 20 December 2006.
- 494 34. Nutrition and Health Claims. Available online: [https://food.ec.europa.eu/safety/labelling-and-](https://food.ec.europa.eu/safety/labelling-and-nutrition/nutrition-and-health-claims_en)
495 [nutrition/nutrition-and-health-claims_en](https://food.ec.europa.eu/safety/labelling-and-nutrition/nutrition-and-health-claims_en). [Accessed on 2023 Mar 7]
- 496 35. Label Claims for Conventional Foods and Dietary Supplements. Available online:
497 <https://www.fda.gov/food/food-labeling-nutrition/label-claims-conventional-foods-and-dietary-supplements>
498 [Accessed on 2022 Jul 3]
- 499 36. Amagase A. US Dietary Supplement Labeling Rules and the Possibility of Medical Cost Reduction. *J Nutr Sci*
500 *Vitaminol (Tokyo)*. 2015;61 Suppl:S136-8. doi: 10.3177/jnsv.61.S136.
- 501 37. Turner RE, Degnan FH, Archer DL. Label claims for foods and supplements: a review of the regulations. *Nutr*
502 *Clin Pract*. 2005 Feb;20(1):21-32. doi: 10.1177/011542650502000121.
- 503 38. Bernstein L, Rohr F, Helm JR, Nutrition management of inherited metabolic diseases. Ed. Springer Book, 2015
- 504 39. Gomes F, et al. ESPEN guidelines on nutritional support for polymorbid internal medicine patients. *Clin Nutr*.
505 2018.
- 506 40. IRS. Publication 502 (2023), Medical and Dental Expenses
- 507 41. FDA. FDA Announcing Public Meeting to Discuss Responsible Innovation in Dietary Supplements. Available
508 from: [https://www.fda.gov/food/cfsan-constituent-updates/fda-announcing-public-meeting-discuss-](https://www.fda.gov/food/cfsan-constituent-updates/fda-announcing-public-meeting-discuss-responsible-innovation-dietary-supplements)
509 [responsible-innovation-dietary-supplements](https://www.fda.gov/food/cfsan-constituent-updates/fda-announcing-public-meeting-discuss-responsible-innovation-dietary-supplements). [updated April 10, 2019]
- 510

511

512

Class of food derivates	European definition	European regulation	American definition	American regulation
Foods for specific groups (FSG): early childhood foods, foods for special medical purposes, foods presented as total dietary substitutes	Products intended for specific population groups with special nutritional needs, made nutritionally vulnerable by certain disorders or diseases	Regulation 609/2013 (EU)	None specifically addressed	None specifically addressed
Infant formulas	Products expressly intended for infants (subjects younger than 12 months)	Regulation 2016/127 (EU)	Infant formula is a food that may be the sole source of nutrition for infants (i.e., children up to 12 months of age) as an alternative to human milk.	FD&C Act section n. 412
Foods for special medical purposes / Medical foods	A food product expressly prepared or formulated and intended for the dietary management of patients, including infants, to be used under medical supervision	Regulation 2016/128 (EU)	A food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements	Orphan Drug Act (section 5(b)(3))
Total dietary substitutes	Products that must provide a daily energy intake of between 600 and 1200 kcalories	Regulation 2017/1798 (EU)	None specifically addressed	None specifically addressed
Gluten-free foods	Products specifically formulated for celiac people	Regulation 828/2014 (EU)	Any foods that carry the label “gluten-free,” “no gluten,” “free of gluten,” or “without gluten” must contain less than 20 parts per million (ppm) of gluten.	Code of Federal Regulations (CFR) - Title 21, part 101

Foods with added vitamins and minerals/ fortified foods	Products where vitamins and minerals have been added voluntarily, in accordance with Regulation (EC) 1925/2006, which lists the list of permitted vitamins and minerals along with the list of their sources	Regulation (EC) 1925/2006	Food added with one or more vitamins or minerals or protein	Code of Federal Regulations Title 21 Part 104 Subpart B
Food supplements (FS)/ Dietary supplements (DS)	Food products intended to supplement the common diet and which are a concentrated source of nutrients, such as vitamins and minerals, or other substances having a nutritional or physiological effect	Directive 46/2002 (EC)	A dietary substance for use by man to supplement the diet by increasing the total dietary intake	Dietary Supplement Health and Education Act (DSHEA), 1994

513
514
515
516
517
518

Table 1. Definitions of products under food regulations in the European Union and in the United States of America.

OBJECT OF THE REGULATION	EUROPEAN DEFINITION	EUROPEAN REGULATION	AMERICAN DEFINITION	AMERICAN REGULATION
Food / conventional food	General principles and requirements of food law	Regulation (EC) n. 178/2002	Articles used for food or drink for man or other animals, chewing gum, and articles used for components of any such article	Federal Food, Drug and Cosmetic Act 4, section 201 (FD&C Act)
Mandatory food information and labeling	Principles, requirements and responsibilities governing mandatory food information and food labeling	Regulation 1169/2011	Identity labeling of food in packaged form	Code of Federal Regulations Title 21 Part 101
Addition of vitamins and minerals and other substances to foods	Products where vitamins and minerals have been added voluntarily	Regulation (EC) 1925/2006	Products where vitamins or minerals or proteins have been added	Code of Federal Regulations Title 21 Part 104 Subpart B
Novel foods/new dietary ingredients	The ingredients in the FS and in all the foods without a significant history of consumption before May 15, 1997	Regulation (EU) 2015/2283	Ingredients that have been not marketed in the USA prior to October 15, 1994	Federal food, drug, and cosmetic act (FD&C Act), section n.201
Health and nutritional claims / Health claims, nutrient content claims, and structure/function claims.	<p><i>Nutritional Claims:</i> any indication which states, suggests or implies that a food owns particular beneficial nutritional properties</p> <p><i>Health Claims:</i> any claim which states, suggests or implies the existence of a relationship between a specific food component and health</p>	Regulation (EU) 1924/2006	<ul style="list-style-type: none"> Health claims describe the relationship between a food substance and reduced risk of a disease or health-related condition Nutrient Content Claims describe the level of a nutrient in a product Structure/Function Claims describe the role of a nutrient or dietary ingredient in maintaining normal body structures or functions 	<ol style="list-style-type: none"> 1990 Nutrition Labeling and Education Act (NLEA) 1997 Food and Drug Administration Modernization Act (FDAMA) Interim Procedures

Vitamins and minerals and their forms	Vitamins and minerals and their forms that may be added to foods and in particular to food supplements	Regulation (EC) 1170/2009	None specifically addressed	None specifically addressed
---------------------------------------	--	---------------------------	-----------------------------	-----------------------------

519

520

521 **Table 2.** Regulatory framework concerning food supplements in the European Union and the Unites States of
522 America.

523

524